Fusion Biopsy, not Cognitive, Is the New Gold Standard

To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and hig...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Alessandro Marquis [verfasserIn] Giancarlo Marra [verfasserIn] Paolo Gontero [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer

Übergeordnetes Werk:	In: Société Internationale d’Urologie Journal - MDPI AG, 2021, 4(2023), 2, Seite 142-144
Übergeordnetes Werk:	volume:4 ; year:2023 ; number:2 ; pages:142-144

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.48083/RYRF4858

Katalog-ID:	DOAJ097978337

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ097978337
003	DE-627
005	20240414000510.0
007	cr uuu---uuuuu
008	240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.48083/RYRF4858 \|2 doi
035			\|a (DE-627)DOAJ097978337
035			\|a (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC870-923
100	0		\|a Alessandro Marquis \|e verfasserin \|4 aut
245	1	0	\|a Fusion Biopsy, not Cognitive, Is the New Gold Standard
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB.
650		4	\|a prostate biopsy
650		4	\|a targeted prostate biopsy
650		4	\|a fusion prostate biopsy
650		4	\|a cognitive prostate biopsy
650		4	\|a prostate cancer
653		0	\|a Diseases of the genitourinary system. Urology
700	0		\|a Giancarlo Marra \|e verfasserin \|4 aut
700	0		\|a Paolo Gontero \|e verfasserin \|4 aut
773	0	8	\|i In \|t Société Internationale d’Urologie Journal \|d MDPI AG, 2021 \|g 4(2023), 2, Seite 142-144 \|w (DE-627)1767701322 \|w (DE-600)3091153-9 \|x 25636499 \|7 nnns
773	1	8	\|g volume:4 \|g year:2023 \|g number:2 \|g pages:142-144
856	4	0	\|u https://doi.org/10.48083/RYRF4858 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 \|z kostenfrei
856	4	0	\|u https://siuj.org/index.php/siuj/article/view/253/197 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2563-6499 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2023 \|e 2 \|h 142-144

Indexfelder

author_variant	a m am g m gm p g pg
matchkey_str	article:25636499:2023----::uinipyocgiieshnw
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.48083/RYRF4858 doi (DE-627)DOAJ097978337 (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805 DE-627 ger DE-627 rakwb eng RC870-923 Alessandro Marquis verfasserin aut Fusion Biopsy, not Cognitive, Is the New Gold Standard 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB. prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer Diseases of the genitourinary system. Urology Giancarlo Marra verfasserin aut Paolo Gontero verfasserin aut In Société Internationale d’Urologie Journal MDPI AG, 2021 4(2023), 2, Seite 142-144 (DE-627)1767701322 (DE-600)3091153-9 25636499 nnns volume:4 year:2023 number:2 pages:142-144 https://doi.org/10.48083/RYRF4858 kostenfrei https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 kostenfrei https://siuj.org/index.php/siuj/article/view/253/197 kostenfrei https://doaj.org/toc/2563-6499 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2023 2 142-144
spelling	10.48083/RYRF4858 doi (DE-627)DOAJ097978337 (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805 DE-627 ger DE-627 rakwb eng RC870-923 Alessandro Marquis verfasserin aut Fusion Biopsy, not Cognitive, Is the New Gold Standard 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB. prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer Diseases of the genitourinary system. Urology Giancarlo Marra verfasserin aut Paolo Gontero verfasserin aut In Société Internationale d’Urologie Journal MDPI AG, 2021 4(2023), 2, Seite 142-144 (DE-627)1767701322 (DE-600)3091153-9 25636499 nnns volume:4 year:2023 number:2 pages:142-144 https://doi.org/10.48083/RYRF4858 kostenfrei https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 kostenfrei https://siuj.org/index.php/siuj/article/view/253/197 kostenfrei https://doaj.org/toc/2563-6499 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2023 2 142-144
allfields_unstemmed	10.48083/RYRF4858 doi (DE-627)DOAJ097978337 (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805 DE-627 ger DE-627 rakwb eng RC870-923 Alessandro Marquis verfasserin aut Fusion Biopsy, not Cognitive, Is the New Gold Standard 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB. prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer Diseases of the genitourinary system. Urology Giancarlo Marra verfasserin aut Paolo Gontero verfasserin aut In Société Internationale d’Urologie Journal MDPI AG, 2021 4(2023), 2, Seite 142-144 (DE-627)1767701322 (DE-600)3091153-9 25636499 nnns volume:4 year:2023 number:2 pages:142-144 https://doi.org/10.48083/RYRF4858 kostenfrei https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 kostenfrei https://siuj.org/index.php/siuj/article/view/253/197 kostenfrei https://doaj.org/toc/2563-6499 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2023 2 142-144
allfieldsGer	10.48083/RYRF4858 doi (DE-627)DOAJ097978337 (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805 DE-627 ger DE-627 rakwb eng RC870-923 Alessandro Marquis verfasserin aut Fusion Biopsy, not Cognitive, Is the New Gold Standard 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB. prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer Diseases of the genitourinary system. Urology Giancarlo Marra verfasserin aut Paolo Gontero verfasserin aut In Société Internationale d’Urologie Journal MDPI AG, 2021 4(2023), 2, Seite 142-144 (DE-627)1767701322 (DE-600)3091153-9 25636499 nnns volume:4 year:2023 number:2 pages:142-144 https://doi.org/10.48083/RYRF4858 kostenfrei https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 kostenfrei https://siuj.org/index.php/siuj/article/view/253/197 kostenfrei https://doaj.org/toc/2563-6499 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2023 2 142-144
allfieldsSound	10.48083/RYRF4858 doi (DE-627)DOAJ097978337 (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805 DE-627 ger DE-627 rakwb eng RC870-923 Alessandro Marquis verfasserin aut Fusion Biopsy, not Cognitive, Is the New Gold Standard 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB. prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer Diseases of the genitourinary system. Urology Giancarlo Marra verfasserin aut Paolo Gontero verfasserin aut In Société Internationale d’Urologie Journal MDPI AG, 2021 4(2023), 2, Seite 142-144 (DE-627)1767701322 (DE-600)3091153-9 25636499 nnns volume:4 year:2023 number:2 pages:142-144 https://doi.org/10.48083/RYRF4858 kostenfrei https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 kostenfrei https://siuj.org/index.php/siuj/article/view/253/197 kostenfrei https://doaj.org/toc/2563-6499 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2023 2 142-144
language	English
source	In Société Internationale d’Urologie Journal 4(2023), 2, Seite 142-144 volume:4 year:2023 number:2 pages:142-144
sourceStr	In Société Internationale d’Urologie Journal 4(2023), 2, Seite 142-144 volume:4 year:2023 number:2 pages:142-144
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer Diseases of the genitourinary system. Urology
isfreeaccess_bool	true
container_title	Société Internationale d’Urologie Journal
authorswithroles_txt_mv	Alessandro Marquis @@aut@@ Giancarlo Marra @@aut@@ Paolo Gontero @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	1767701322
id	DOAJ097978337
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ097978337</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414000510.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.48083/RYRF4858</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097978337</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ80b5db3d900b468cb3b37574db39e805</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Alessandro Marquis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fusion Biopsy, not Cognitive, Is the New Gold Standard</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fusion prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cognitive prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giancarlo Marra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Gontero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Société Internationale d’Urologie Journal</subfield><subfield code="d">MDPI AG, 2021</subfield><subfield code="g">4(2023), 2, Seite 142-144</subfield><subfield code="w">(DE-627)1767701322</subfield><subfield code="w">(DE-600)3091153-9</subfield><subfield code="x">25636499</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:142-144</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.48083/RYRF4858</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/80b5db3d900b468cb3b37574db39e805</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://siuj.org/index.php/siuj/article/view/253/197</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2563-6499</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="h">142-144</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Alessandro Marquis
spellingShingle	Alessandro Marquis misc RC870-923 misc prostate biopsy misc targeted prostate biopsy misc fusion prostate biopsy misc cognitive prostate biopsy misc prostate cancer misc Diseases of the genitourinary system. Urology Fusion Biopsy, not Cognitive, Is the New Gold Standard
authorStr	Alessandro Marquis
ppnlink_with_tag_str_mv	@@773@@(DE-627)1767701322
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC870-923
illustrated	Not Illustrated
issn	25636499
topic_title	RC870-923 Fusion Biopsy, not Cognitive, Is the New Gold Standard prostate biopsy targeted prostate biopsy fusion prostate biopsy cognitive prostate biopsy prostate cancer
topic	misc RC870-923 misc prostate biopsy misc targeted prostate biopsy misc fusion prostate biopsy misc cognitive prostate biopsy misc prostate cancer misc Diseases of the genitourinary system. Urology
topic_unstemmed	misc RC870-923 misc prostate biopsy misc targeted prostate biopsy misc fusion prostate biopsy misc cognitive prostate biopsy misc prostate cancer misc Diseases of the genitourinary system. Urology
topic_browse	misc RC870-923 misc prostate biopsy misc targeted prostate biopsy misc fusion prostate biopsy misc cognitive prostate biopsy misc prostate cancer misc Diseases of the genitourinary system. Urology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Société Internationale d’Urologie Journal
hierarchy_parent_id	1767701322
hierarchy_top_title	Société Internationale d’Urologie Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1767701322 (DE-600)3091153-9
title	Fusion Biopsy, not Cognitive, Is the New Gold Standard
ctrlnum	(DE-627)DOAJ097978337 (DE-599)DOAJ80b5db3d900b468cb3b37574db39e805
title_full	Fusion Biopsy, not Cognitive, Is the New Gold Standard
author_sort	Alessandro Marquis
journal	Société Internationale d’Urologie Journal
journalStr	Société Internationale d’Urologie Journal
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	142
author_browse	Alessandro Marquis Giancarlo Marra Paolo Gontero
container_volume	4
class	RC870-923
format_se	Elektronische Aufsätze
author-letter	Alessandro Marquis
doi_str_mv	10.48083/RYRF4858
author2-role	verfasserin
title_sort	fusion biopsy, not cognitive, is the new gold standard
callnumber	RC870-923
title_auth	Fusion Biopsy, not Cognitive, Is the New Gold Standard
abstract	To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB.
abstractGer	To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB.
abstract_unstemmed	To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Fusion Biopsy, not Cognitive, Is the New Gold Standard
url	https://doi.org/10.48083/RYRF4858 https://doaj.org/article/80b5db3d900b468cb3b37574db39e805 https://siuj.org/index.php/siuj/article/view/253/197 https://doaj.org/toc/2563-6499
remote_bool	true
author2	Giancarlo Marra Paolo Gontero
author2Str	Giancarlo Marra Paolo Gontero
ppnlink	1767701322
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.48083/RYRF4858
callnumber-a	RC870-923
up_date	2024-07-03T14:47:09.865Z
_version_	1803569625681625088
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ097978337</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414000510.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.48083/RYRF4858</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097978337</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ80b5db3d900b468cb3b37574db39e805</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Alessandro Marquis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fusion Biopsy, not Cognitive, Is the New Gold Standard</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To date, although some benefits resulting from a software-guided technique are undeniable, no clear superiority of fusion over cognitive targeted biopsy (COG-TB) has been supported by strong evidence. We discuss potential causes of trials failing to show the superiority of fusion TB (FUS-TB) and highlight its advantages over the cognitive approach.One possible reason why current literature showed contradictory evidence in supporting FUS-TB may be the lack of high-quality well-designed trials. Indeed, most of the studies addressing this issue have considerable limitations, such as underpowering, small sample size, lack of randomization, and poor generalizability. A second reason may be the inclusion in the majority of trials of a wide spectrum of MRI-lesions, a scenario in which the benefits of FUS-TB may be less evident. In fact, some of the few studies considering smaller targets demonstrated higher accuracy for the FUS technique. As concerns the advantages of FUS-TB, the opportunity offered by some fusion systems of storing information useful for planning and/or follow-up active surveillance, focal therapy, and radical prostatectomy, as well as a reported faster learning curve, are strong points supporting the fusion approach.In conclusion, the potential advantages when targeting smaller lesions together with the storage capability to guide patient management after the biopsy and an easier learning curve may make the FUS approach the more appropriate technique for performing TB.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fusion prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cognitive prostate biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giancarlo Marra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Gontero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Société Internationale d’Urologie Journal</subfield><subfield code="d">MDPI AG, 2021</subfield><subfield code="g">4(2023), 2, Seite 142-144</subfield><subfield code="w">(DE-627)1767701322</subfield><subfield code="w">(DE-600)3091153-9</subfield><subfield code="x">25636499</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:142-144</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.48083/RYRF4858</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/80b5db3d900b468cb3b37574db39e805</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://siuj.org/index.php/siuj/article/view/253/197</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2563-6499</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="h">142-144</subfield></datafield></record></collection>
score	7.4021244

Nicht das Richtige dabei?

Schreiben Sie uns!

Fusion Biopsy, not Cognitive, Is the New Gold Standard

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?